Correlation Between Tarsus Pharmaceuticals and Allovir

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tarsus Pharmaceuticals and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tarsus Pharmaceuticals and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tarsus Pharmaceuticals and Allovir, you can compare the effects of market volatilities on Tarsus Pharmaceuticals and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tarsus Pharmaceuticals with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tarsus Pharmaceuticals and Allovir.

Diversification Opportunities for Tarsus Pharmaceuticals and Allovir

-0.6
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Tarsus and Allovir is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Tarsus Pharmaceuticals and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Tarsus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tarsus Pharmaceuticals are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Tarsus Pharmaceuticals i.e., Tarsus Pharmaceuticals and Allovir go up and down completely randomly.

Pair Corralation between Tarsus Pharmaceuticals and Allovir

Given the investment horizon of 90 days Tarsus Pharmaceuticals is expected to generate 0.39 times more return on investment than Allovir. However, Tarsus Pharmaceuticals is 2.53 times less risky than Allovir. It trades about 0.29 of its potential returns per unit of risk. Allovir is currently generating about -0.07 per unit of risk. If you would invest  3,188  in Tarsus Pharmaceuticals on September 16, 2024 and sell it today you would earn a total of  2,062  from holding Tarsus Pharmaceuticals or generate 64.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Tarsus Pharmaceuticals  vs.  Allovir

 Performance 
       Timeline  
Tarsus Pharmaceuticals 

Risk-Adjusted Performance

22 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Tarsus Pharmaceuticals are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Tarsus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.
Allovir 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Tarsus Pharmaceuticals and Allovir Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tarsus Pharmaceuticals and Allovir

The main advantage of trading using opposite Tarsus Pharmaceuticals and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tarsus Pharmaceuticals position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.
The idea behind Tarsus Pharmaceuticals and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios